or s compounds of formula ia have particularly advantageous properties which may include biological activities such as modelling of lps included rat neutrophilia selective inhibition of mmp 9 and mmp 12 activity and inhibition of these activities without selectivity towards mmp 1 activity further these advantageous properties may include solubilities which enhance preparation and administration of dosage forms and improved bioavailability as compared to known compounds for example those of wo 2005 026120 in another embodiment the invention relates to compounds of general formula ib denotes or represents a stereogenic or asymmetric center of defined configuration selected from r r s s r s and s r r 1b is optionally substituted phenyl or heteroaryl wherein optional substituents can be selected from with one or more alkyl halo alkoxy trifluoroalkyl or aryl r 2b is 5 6 membered n containing heterocyclyl linked through n atom which is optionally fused to aryl heteroaryl or spirofused to cycloalkyl which can optionally be further substituted with one or more oxo group alkyl cycloalkyl halo alkoxy trifluoroalkyl or aryl compounds of formula ib have particularly advantageous properties which may include biological activities such as modelling of lps included rat neutrophilia selective inhibition of mmp 9 and mmp 12 activity and inhibition of these activities without selectivity towards mmp 1 activity further.